Etoricoxib Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Etoricoxib Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Gouty Arthritis, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The global Etoricoxib market is projected to grow substantially from USD 123.21 Million in 2025 to USD 245.94 Million by 2031, demonstrating a 12.21% CAGR. Etoricoxib, a selective COX-2 inhibitor non-steroidal anti-inflammatory drug (NSAID), provides symptomatic relief for various conditions including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. This market expansion is primarily driven by the increasing global incidence of musculoskeletal disorders and a growing geriatric population, both necessitating effective, long-term pain management solutions with a lower gastrointestinal toxicity profile than conventional NSAIDs. Musculoskeletal conditions already account for 17.1% of global years lived with disability in 2024, creating consistent demand for Etoricoxib in regions where it is authorized.
Market Driver
The primary driver for the Etoricoxib market is the rising global prevalence of chronic musculoskeletal disorders such as osteoarthritis and rheumatoid arthritis, which creates a significant demand for effective anti-inflammatory therapies. These conditions often require prolonged pain management, intensifying the need for selective COX-2 inhibitors like Etoricoxib in approved markets. For instance, global rheumatoid arthritis cases are anticipated to increase by approximately 80.2% from 2020 levels by 2050, directly boosting the consumption of Etoricoxib. Additionally, the expanding geriatric population, which constituted 10.3% of individuals aged 65 and older in 2024, contributes significantly to market growth due to their susceptibility to chronic musculoskeletal issues and the benefit of Etoricoxib’s reduced risk of gastrointestinal bleeding compared to traditional NSAIDs, as evidenced by a 7% sales increase for Arcoxia in Q1 2024, particularly in the Asia Pacific region.
Market Challenge
The most significant challenge impeding the Global Etoricoxib Market's growth is the strict regulatory exclusion imposed by the US Food and Drug Administration (FDA) due to concerns about cardiovascular thrombotic risks. This lack of FDA approval effectively prevents Etoricoxib from accessing the United States, which is the world's largest and most lucrative pharmaceutical market. Consequently, manufacturers are forced to limit their commercial operations primarily to European and Asia-Pacific regions, thereby severely capping the drug's overall revenue potential. With North America alone accounting for 54.8% of estimated global pharmaceutical sales in 2024, this regulatory barrier structurally constrains Etoricoxib's growth trajectory, regardless of its efficacy or demand in authorized territories.
Market Trends
Two notable trends are reshaping the Etoricoxib market. Firstly, there is a proliferation of Fixed-Dose Combinations (FDCs) that integrate muscle relaxants and opioids, aiming to enhance therapeutic efficacy through multimodal analgesia, improve patient compliance, and reduce the burden of multiple pills. Pharmaceutical companies are developing biphasic and combination therapies, such as Etoricoxib paired with Tramadol or Thiocolchicoside, to provide superior relief for acute musculoskeletal conditions, exemplified by a study on an Etoricoxib-Tramadol biphasic tablet demonstrating equivalent efficacy with simplified dosing. Secondly, a surge in generic manufacturing and exports from Asia-Pacific hubs, particularly India and China, is transforming the global supply chain. These regions are leveraging cost-efficient production capabilities to become the primary suppliers of non-steroidal anti-inflammatory formulations for markets that accept Etoricoxib, meeting demand in Europe, Latin America, and the Middle East, as underscored by India's pharmaceutical exports reaching USD 30.47 billion in fiscal year 2024-25.
Key Market Players
* Merck & Co., Inc.
* Sun Pharmaceutical Industries Limited
* Dr. Reddy’s Laboratories Limited
* Cipla Limited
* Lupin Limited
* Torrent Pharmaceuticals Limited
* Zydus Lifesciences Limited
* Aurobindo Pharma Limited
* Teva Pharmaceutical Industries Ltd.
* Alkem Laboratories Limited
Report Scope
In this report, the Global Etoricoxib Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Etoricoxib Market, By Sales Channel
* Direct
* Indirect
# Etoricoxib Market, By End Use
* Osteoarthritis
* Rheumatoid Arthritis
* Ankylosing Spondylitis
* Acute Gouty Arthritis
* Others
# Etoricoxib Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Etoricoxib Market.
Available Customizations:
Global Etoricoxib Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Etoricoxib Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Sales Channel (Direct, Indirect)
5.2.2. By End Use (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Gouty Arthritis, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Etoricoxib Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Sales Channel
6.2.2. By End Use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Etoricoxib Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Sales Channel
6.3.1.2.2. By End Use
6.3.2. Canada Etoricoxib Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Sales Channel
6.3.2.2.2. By End Use
6.3.3. Mexico Etoricoxib Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Sales Channel
6.3.3.2.2. By End Use
7. Europe Etoricoxib Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Sales Channel
7.2.2. By End Use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Etoricoxib Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Sales Channel
7.3.1.2.2. By End Use
7.3.2. France Etoricoxib Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Sales Channel
7.3.2.2.2. By End Use
7.3.3. United Kingdom Etoricoxib Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Sales Channel
7.3.3.2.2. By End Use
7.3.4. Italy Etoricoxib Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Sales Channel
7.3.4.2.2. By End Use
7.3.5. Spain Etoricoxib Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Sales Channel
7.3.5.2.2. By End Use
8. Asia Pacific Etoricoxib Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Sales Channel
8.2.2. By End Use
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Etoricoxib Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Sales Channel
8.3.1.2.2. By End Use
8.3.2. India Etoricoxib Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Sales Channel
8.3.2.2.2. By End Use
8.3.3. Japan Etoricoxib Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Sales Channel
8.3.3.2.2. By End Use
8.3.4. South Korea Etoricoxib Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Sales Channel
8.3.4.2.2. By End Use
8.3.5. Australia Etoricoxib Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Sales Channel
8.3.5.2.2. By End Use
9. Middle East & Africa Etoricoxib Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Sales Channel
9.2.2. By End Use
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Etoricoxib Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Sales Channel
9.3.1.2.2. By End Use
9.3.2. UAE Etoricoxib Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Sales Channel
9.3.2.2.2. By End Use
9.3.3. South Africa Etoricoxib Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Sales Channel
9.3.3.2.2. By End Use
10. South America Etoricoxib Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Sales Channel
10.2.2. By End Use
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Etoricoxib Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Sales Channel
10.3.1.2.2. By End Use
10.3.2. Colombia Etoricoxib Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Sales Channel
10.3.2.2.2. By End Use
10.3.3. Argentina Etoricoxib Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Sales Channel
10.3.3.2.2. By End Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Etoricoxib Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Merck & Co., Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Sun Pharmaceutical Industries Limited
15.3. Dr. Reddy’s Laboratories Limited
15.4. Cipla Limited
15.5. Lupin Limited
15.6. Torrent Pharmaceuticals Limited
15.7. Zydus Lifesciences Limited
15.8. Aurobindo Pharma Limited
15.9. Teva Pharmaceutical Industries Ltd.
15.10. Alkem Laboratories Limited
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們